Search
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalThis binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and
Diphenhydramine
go.drugbank.com/drugs/DB01075ApprovedInvestigationalAs a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.
Mixtures: ConRx PM, ZoDen PDCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesRopeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials. … [A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients.
Synonyms: PEG-P-IFN-alfa-2b, PEG-P-IFN-alpha-2bCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2A6 InhibitorsDurvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[A192789] Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture,[L12621] durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsBelzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L64571] On September 24, 2026, the FDA approved belzutifan in combination with lenvatinib for advanced ccRCC following a PD-1 or PD-L1 inhibitor.[L64572]
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesAsciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigationalAsciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). … [L39005] It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesFentanyl
go.drugbank.com/drugs/DB00813ApprovedIllicitInvestigationalVet approvedFentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L66...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: FENTANYL-PF 100 MCG/2 ML I.V./I.M. ENJEKSİYONLUK ÇÖZELTİ, 10 ADET, FENTANYL-PF 500 MCG/10 ML I.V./I.M. ENJEKSİYONLUK ÇÖZELTİ, 1 ADETMetformin
go.drugbank.com/drugs/DB00331ApprovedInvestigationalMetformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes. Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabe...
Products: KETAMET-PR, Pg-metforminSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalfor tumors with PD-L1 CPS ≥ 10. … [L47606, L47601] The FDA approved first-line TNBC indications on June 24, 2026, as a single agent for patients who are not candidates for PD-1 or PD-L1 inhibitor-based therapy and in combination with pembrolizumab